Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations

The goal is to support your bodys natural signals, not override them
Medical News Today Harvard Health Publishing
6 When to speak to a healthcare professional Speak to your GP or a regulated UK clinician if you experience any of the following: Nausea or vomiting that lasts more than 24 hours, or that stops you from keeping fluids down Persistent or severe abdominal pain, especially if it radiates to your back (a possible sign of pancreatitis) Sudden, severe pain in the upper right side of your abdomen (a possible sign of gallstones or gallbladder inflammation) Persistent burning, tingling, or unusual skin sensitivity Palpitations, a sustained racing heart, dizziness, or chest discomfort Yellowing of the skin or eyes, dark urine, or pale stools (possible signs of liver problems) Signs of dehydration: dry mouth, low urine output, dizziness on standing, confusion Low mood, anxiety, or thoughts of self-harm If you bought retatrutide online and notice any new or unexpected symptoms Retatrutide isnt currently MHRA-approved

AOD-9604 (Advanced Obesity Drug peptide) is a research-grade peptide derived from the C-terminus of human growth hormone (HGH), specifically the 176191 amino acid sequence
Common GI Side Effects of GLP-1 Therapy (and Their Overlap with IBS) It bears repeating just how common gastrointestinal side effects are with GLP-1 agonists, and these side effects often mirror IBS symptoms